Nonspecific immunotherapy by Corynebacterium parvum. Phase I toxicity study in 12 patients with advanced cancer

V. S T Cheng, H. D. Suit, C. C. Wang, Charles W Cummings

Research output: Contribution to journalArticle

Abstract

Corynebacterium parvum, a non specific immunopotentiator, was administered intravenously to 12 patients with advanced cancer at 2, 3, and 4 mg/m2 dose levels in combination with radiation therapy. One dose of C. parvum was given every 7 days for a total of 4 doses in 21 days. Symptoms and signs developed by these patients for a period of 3 to 6 hours during and shortly after the i.v. infusion of the first dose of C. parvum were moderately severe in nine patients and mild in three patients. For the second, third, and fourth doses of C. parvum, patients had fewer and less intense reactions and were given their treatments on an outpatient basis. There was no added morbidity to the patients' tolerance to either palliative or radical dose levels of radiation therapy. Changes in renal, hepatic, hematologic, and immunologic functions were minimal. At the above dose levels, the use of C. parvum to stimulate the reticuloendothelial system in humans by the intravenous route can be safe and well tolerated provided the side effects are appreciated and symptomatic treatments administered.

Original languageEnglish (US)
Pages (from-to)1687-1695
Number of pages9
JournalCancer
Volume37
Issue number4
StatePublished - 1976
Externally publishedYes

Fingerprint

Propionibacterium acnes
Immunotherapy
Neoplasms
Radiotherapy
Immunologic Adjuvants
Mononuclear Phagocyte System
Signs and Symptoms
Outpatients
Morbidity
Kidney
Liver
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nonspecific immunotherapy by Corynebacterium parvum. Phase I toxicity study in 12 patients with advanced cancer. / Cheng, V. S T; Suit, H. D.; Wang, C. C.; Cummings, Charles W.

In: Cancer, Vol. 37, No. 4, 1976, p. 1687-1695.

Research output: Contribution to journalArticle

@article{4616795191ab4525b36a9e6411240ce7,
title = "Nonspecific immunotherapy by Corynebacterium parvum. Phase I toxicity study in 12 patients with advanced cancer",
abstract = "Corynebacterium parvum, a non specific immunopotentiator, was administered intravenously to 12 patients with advanced cancer at 2, 3, and 4 mg/m2 dose levels in combination with radiation therapy. One dose of C. parvum was given every 7 days for a total of 4 doses in 21 days. Symptoms and signs developed by these patients for a period of 3 to 6 hours during and shortly after the i.v. infusion of the first dose of C. parvum were moderately severe in nine patients and mild in three patients. For the second, third, and fourth doses of C. parvum, patients had fewer and less intense reactions and were given their treatments on an outpatient basis. There was no added morbidity to the patients' tolerance to either palliative or radical dose levels of radiation therapy. Changes in renal, hepatic, hematologic, and immunologic functions were minimal. At the above dose levels, the use of C. parvum to stimulate the reticuloendothelial system in humans by the intravenous route can be safe and well tolerated provided the side effects are appreciated and symptomatic treatments administered.",
author = "Cheng, {V. S T} and Suit, {H. D.} and Wang, {C. C.} and Cummings, {Charles W}",
year = "1976",
language = "English (US)",
volume = "37",
pages = "1687--1695",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Nonspecific immunotherapy by Corynebacterium parvum. Phase I toxicity study in 12 patients with advanced cancer

AU - Cheng, V. S T

AU - Suit, H. D.

AU - Wang, C. C.

AU - Cummings, Charles W

PY - 1976

Y1 - 1976

N2 - Corynebacterium parvum, a non specific immunopotentiator, was administered intravenously to 12 patients with advanced cancer at 2, 3, and 4 mg/m2 dose levels in combination with radiation therapy. One dose of C. parvum was given every 7 days for a total of 4 doses in 21 days. Symptoms and signs developed by these patients for a period of 3 to 6 hours during and shortly after the i.v. infusion of the first dose of C. parvum were moderately severe in nine patients and mild in three patients. For the second, third, and fourth doses of C. parvum, patients had fewer and less intense reactions and were given their treatments on an outpatient basis. There was no added morbidity to the patients' tolerance to either palliative or radical dose levels of radiation therapy. Changes in renal, hepatic, hematologic, and immunologic functions were minimal. At the above dose levels, the use of C. parvum to stimulate the reticuloendothelial system in humans by the intravenous route can be safe and well tolerated provided the side effects are appreciated and symptomatic treatments administered.

AB - Corynebacterium parvum, a non specific immunopotentiator, was administered intravenously to 12 patients with advanced cancer at 2, 3, and 4 mg/m2 dose levels in combination with radiation therapy. One dose of C. parvum was given every 7 days for a total of 4 doses in 21 days. Symptoms and signs developed by these patients for a period of 3 to 6 hours during and shortly after the i.v. infusion of the first dose of C. parvum were moderately severe in nine patients and mild in three patients. For the second, third, and fourth doses of C. parvum, patients had fewer and less intense reactions and were given their treatments on an outpatient basis. There was no added morbidity to the patients' tolerance to either palliative or radical dose levels of radiation therapy. Changes in renal, hepatic, hematologic, and immunologic functions were minimal. At the above dose levels, the use of C. parvum to stimulate the reticuloendothelial system in humans by the intravenous route can be safe and well tolerated provided the side effects are appreciated and symptomatic treatments administered.

UR - http://www.scopus.com/inward/record.url?scp=0017165563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017165563&partnerID=8YFLogxK

M3 - Article

C2 - 769937

AN - SCOPUS:0017165563

VL - 37

SP - 1687

EP - 1695

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -